Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1465-542X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status ; volume:9 ; number:5 ; day:26 ; month:10 ; year:2007 ; pages:1-8 ; date:10.2007
Breast cancer research ; 9, Heft 5 (26.10.2007), 1-8, 10.2007

Creator: Fehm, Tanja

Contributor: Becker, Sven
Duerr-Stoerzer, Silke
Sotlar, Karl
Mueller, Volkmar
Wallwiener, Diethelm
Lane, Nancy
Solomayer, Erich
Uhr, Jonathan
SpringerLink (Online service)

DOI: 10.1186/bcr1783

URN: urn:nbn:de:1111-2016032363605

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:02 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Fehm, Tanja
Becker, Sven
Duerr-Stoerzer, Silke
Sotlar, Karl
Mueller, Volkmar
Wallwiener, Diethelm
Lane, Nancy
Solomayer, Erich
Uhr, Jonathan
SpringerLink (Online service)

Other Objects (12)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

Hormon- und HER2-Rezeptorstatus beim Mammakarzinom: Bestimmung an der sonografisch gesteuerten Stanzbiopsie und Vergleich mit dem Exzisionspräparat unter Berücksichtigung der Tumorheterogenität

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

Hormon- und HER2-Rezeptorstatus beim Mammakarzinom: Bestimmung an der sonografisch gesteuerten Stanzbiopsie und Vergleich mit dem Exzisionspräparat unter Berücksichtigung der Tumorheterogenität

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

Hormon- und HER2-Rezeptorstatus beim Mammakarzinom: Bestimmung an der sonografisch gesteuerten Stanzbiopsie und Vergleich mit dem Exzisionspräparat unter Berücksichtigung der Tumorheterogenität

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

Hormon- und HER2-Rezeptorstatus beim Mammakarzinom: Bestimmung an der sonografisch gesteuerten Stanzbiopsie und Vergleich mit dem Exzisionspräparat unter Berücksichtigung der Tumorheterogenität

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

Hormon- und HER2-Rezeptorstatus beim Mammakarzinom: Bestimmung an der sonografisch gesteuerten Stanzbiopsie und Vergleich mit dem Exzisionspräparat unter Berücksichtigung der Tumorheterogenität

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

Hormon- und HER2-Rezeptorstatus beim Mammakarzinom: Bestimmung an der sonografisch gesteuerten Stanzbiopsie und Vergleich mit dem Exzisionspräparat unter Berücksichtigung der Tumorheterogenität

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Related objects

Reset password